Patents – Page 2
-
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
Business‘No deal’ Brexit guidance fails to reassure UK chemical industry
UK government issues guidance on chemical regulation and patent law if the UK leaves the EU without agreement
-
ArticleThe dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
WhitepaperA guide to searching and using Markush structures
Chemical patents are often very long and difficult to read. Markush searching can enable you to easily categorise and filter the information you need, giving you the insights that a paper sometimes cannot.
-
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessUS government urged to exercise drug patent rights
Campaign group says withdrawing Biogen’s license to government patents, or re-licensing them to other companies, could lower MS drug prices
-
BusinessAllergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
BusinessUS court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
BusinessBroad Institute backs central Crispr patent licensing platform
Key players submit 22 patents to pool, and urge other holders to create a one-stop shop for licensing deals
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
BusinessSilence Therapeutics and Alnylam in patent dispute
Suit alleges competitors need to license Silence patents relating to their drug cantidates
-
BusinessUS supreme court limits patent rights
Biotech industry is concerned that ruling will hit small companies
-
NewsLegal battles stall US biosimilars
Unclear legislation and lack of regulatory guidance means companies are turning to the courts
-
OpinionTime to stop using patents to measure innovation in universities
The number of filed patents is a misleading metric for assessing academic research
-
BusinessLilly loses arbitration over Canadian patents
Firm had sought recompense under the Nafta trade agreement
-
OpinionWhy patents will shape the future of battery science
Chemical innovations could lead to new approaches to intellectual property
-
BusinessCrispr patent ruling breaks deadlock
Both sides claim victory as board rules patents do not interfere with each other
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy